| Title： | KSUMC Evidenced-Based Clinical Practice Guideline for Management of Dyslipidemia and Prevention of Atherosclerosis |
| Edition： | Updated |
| Classification： | Standard guideline |
| Field： | Comprehensive guideline |
| Countries and regions： | Saudi Arabia |
| Guidelines users： | Physicians, Nurses, Clinical pharmacist, Dietitians, Allied Health Personnel, Social workers in the following specialties: Family Practice Internal Medicine Cardiology Endocrinology Laboratory Medicine Clinical Pharmacy Clinical Nutrition Health Education |
| Evidence classification method： | The description of the methodology for the production of this adapted CPG can be fulfilled by utilizing the King Saud University (KSU) Modified ADAPTE method. This CPG formal adaptation method included three phases (setup, adaptation, and finalization), nine modules, and 24 steps with modifications in the steps and tools to suit the local general healthcare setting in Saudi Arabia. Overall, the steps of CPG adaptation included the selection of the health topic, formulation of the CPG adaptation working group, identification of health questions using the PIPOH model, searching and selecting Source CPGs with clear inclusion and exclusion criteria, quality assessment of included Source CPGs by using the Appraisal of Guidelines for Research and Evaluation (AGREE) II Instrument, assessment of the currency of the selected Source CPG, drafting of the adapted CPG, external review and consultation process, finalization of the adapted CPG with a set of implementation tools, declaration of conflicts of interests, and finally a plan for review and update. For further details on the specific modifications in steps and tools, refer to the article by Amer et al. 2019 (https://doi.org/10.1111/jep.12927). |
| Development unit： | King Saud University Medical City (KSUMC) |
| Registration time: | 2022-08-22 |
| Registration number： | PREPARE-2022CN545 |
| Purpose of the guideline: | To increase the percentage of patients with (a) coronary heart disease (CHD), (b) with a CHD risk equivalent, or (c) whose 10-year risk is greater than 20% who are on a statin OR have low-density lipoprotein (LDL) <70 ml/Dl To improve the percentage of patients with (a) diabetes and are age 40 and over, or (b) who have a 10 –year Framingham cardiovascular disease (CVD) risk of 10% to 20% who are appropriately treated for lipids. To improve the percentage of patients on lipid-lowering medication who receive regular follow-up care for lipid disorder. To increase the percent of patients on lipid-lowering therapy who remain on therapy |
Latest registration
